AKT1 and non-small cell lung carcinoma: In conclusion, our results are believed to be the first to demonstrate that Sup ODNs have a direct anticancer effect, and increase the sensitivity of A549 NSCLC cells to conventional anticancer drugs by modifying the Akt and ERK1/2 pathway.